Trial Profile
A phase III, multicenter, randomized, double-blind clinical trial to study the safety and efficacy of the addition of sitagliptin (MK0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination with metformin).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 09 Jun 2019 Trial has been completed in Belgium and Bulgaria according to European Clinical Trials Database record.
- 15 Sep 2017 Results (n=1299) of pooled analysis of 2 trials (NCT00395343 and NCT01462266) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 01 Feb 2014 Results published in the Drugs and Aging.